ACO 253

Drug Profile

ACO 253

Alternative Names: AC 253; Antam; GG 747; GR 1150747A

Latest Information Update: 24 Feb 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Islet amyloid polypeptide inhibitors; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 24 Feb 1997 Discontinued-I for Obesity in USA (Unknown route)
  • 24 Feb 1997 Discontinued-I for Type-2 diabetes mellitus in USA (SC)
  • 13 Nov 1995 Phase-I clinical trials for Obesity in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top